×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ALBO

Albireo Pharma Stock Forecast, Price & News

$21.13
+1.27 (+6.39%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$19.51
$21.28
50-Day Range
$18.54
$33.89
52-Week Range
$17.81
$37.86
Volume
305,751 shs
Average Volume
265,333 shs
Market Capitalization
$409.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.67

Albireo Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
243.9% Upside
$72.67 Price Target
Short Interest
Bearish
17.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
0.67mentions of Albireo Pharma in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$56.26 K Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.53) to ($4.01) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.17 out of 5 stars

Medical Sector

300th out of 1,412 stocks

Pharmaceutical Preparations Industry

137th out of 673 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

Albireo Pharma logo

About Albireo Pharma (NASDAQ:ALBO) Stock

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

ALBO Stock News Headlines

Albireo stock plunges on disappointing Q1 result
Albireo Pharma Q1 2022 Earnings Preview
Albireo Pharma's Earnings Outlook
Albireo: A Speculative Play With Upside
Albireo Pharma Q4 2021 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Company Calendar

Last Earnings
5/16/2022
Today
7/03/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$72.67
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+243.9%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-34.03 million
Pretax Margin
-72.02%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
18,394,000
Market Cap
$409.08 million
Optionable
Optionable
Beta
0.92

Social Links















Albireo Pharma Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2022?

3 Wall Street analysts have issued 12 month target prices for Albireo Pharma's shares. Their ALBO stock forecasts range from $66.00 to $80.00. On average, they anticipate Albireo Pharma's stock price to reach $72.67 in the next twelve months. This suggests a possible upside of 243.9% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

How has Albireo Pharma's stock performed in 2022?

Albireo Pharma's stock was trading at $23.29 on January 1st, 2022. Since then, ALBO stock has decreased by 9.3% and is now trading at $21.13.
View the best growth stocks for 2022 here
.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Albireo Pharma
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $0.17. Albireo Pharma had a negative trailing twelve-month return on equity of 73.93% and a negative net margin of 72.02%. During the same period last year, the firm posted ($2.29) EPS.
View Albireo Pharma's earnings history
.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 59, Pay $1.1M)
  • Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 61, Pay $687.78k)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 70, Pay $710.69k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson Ph.D., Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 58)
  • Ms. Joan Connolly, Chief Technology Officer
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 48) (LinkedIn Profile)
  • Ms. Michelle Graham, Chief HR Officer (Age 55)
  • Dr. Kristina Torfgard, VP & Global Project Head
  • Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 54) (LinkedIn Profile)

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $21.13.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $409.08 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 130 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for Albireo Pharma is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.